Powder: -20°C for 3 years | In solvent: -80°C for 1 year
FF-10502 is a pyrimidine nucleoside antimetabolite and a structural analog of Gemcitabine. This compound effectively inhibits DNA polymerase α and β, demonstrating potent anticancer activity by targeting dormant cells.
产品描述 | FF-10502 is a pyrimidine nucleoside antimetabolite and a structural analog of Gemcitabine. This compound effectively inhibits DNA polymerase α and β, demonstrating potent anticancer activity by targeting dormant cells. |
体外活性 | FF-10502 (0.1 nM-10 μM; 72 hours) shows the growth inhibition of pancreatic cancer cell lines, with IC 50 s of 59.9 nM, 39.6 nM, 68.2 nM, and 331.4 nM for BxPC-3, SUIT-2, Capan-1, and MIA PaCa-2 cells, respectively[1]. Cell Viability Assay[1]Cell Line: Human pancreatic cancer cell lines (BxPC-3, SUIT-2, Capan-1, and MIA PaCa-2) Concentration: 0.1 nM to 10 μM Incubation Time: 72 hours Result: Inhibited the growth of pancreatic cancer cell lines. |
体内活性 | FF-10502 (120-480 mg/kg; i.v; once weekly; for 4 weeks) shows an antitumor effect in a mouse xenograft model with the subcutaneously implanted human pancreatic cancer cell line Capan-1[1]. Animal Model: Five-week-old female nude mice (BALB/c-nu/nu) injected with Capan-1 cells[1]. Dosage: 120 mg/kg, 240 mg/kg, 360 mg/kg, and 480 mg/kg Administration: Tail vein injection; once weekly; for 4 weeks Result: Suppressed tumor growth in a dose-dependent manner in mice. |
分子量 | 261.27 |
分子式 | C9H12FN3O3S |
CAS No. | 184302-49-6 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
FF-10502 184302-49-6 FF 10502 FF10502 Inhibitor inhibitor inhibit